APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Genetic Screening for Carrier Diseases

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Genetic Screening for Carrier Diseases Market Analysis and Forecast 2026-2032

Report ID 17414903021 January 2026213 pages

Choose your research edition.

Industry ResearchGenetic Screening for Carrier Diseases Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Genetic Screening for Carrier Diseases Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Genetic Screening for Carrier Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Genetic Screening for Carrier Diseases Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Genetic Screening for Carrier Diseases Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Genetic Screening for Carrier Diseases market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Genetic Screening for Carrier Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Genetic Screening for Carrier Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Genetic Screening for Carrier Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Genetic Screening for Carrier Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Genetic Screening for Carrier Diseases include Thermo Fisher Scientific, Eurofins Scientific, Illumina, Invitae, MedGenome, Myriad Genetics, Roche, Natera and OPKO Health, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Genetic Screening for Carrier Diseases, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Genetic Screening for Carrier Diseases, also provides the revenue of main regions and countries. Of the upcoming market potential for Genetic Screening for Carrier Diseases, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Genetic Screening for Carrier Diseases revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Genetic Screening for Carrier Diseases market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Genetic Screening for Carrier Diseases revenue, projected growth trends, production technology, application and end-user industry.

Genetic Screening for Carrier Diseases Segment by Company

Thermo Fisher Scientific

Eurofins Scientific

Illumina

Invitae

MedGenome

Myriad Genetics

Roche

Natera

OPKO Health

23andMe

bioMérieux

EKF Diagnostics

Gene by Gene (myDNA)

Fulgent Genetics

NxGen MDx

Sonic Genetics

My Baby

AncestryDNA

DiaSorin

Grifols

BGI Genomics

Chigene

Jiajian Medical Testing

Genesky

Berry Genomics

Weihansi Biomedical Technology

Annaroad

Genetic Screening for Carrier Diseases Segment by Type

NGS

Whole Exome Sequencing

Others

Genetic Screening for Carrier Diseases Segment by Application

Couple

Individual

Genetic Screening for Carrier Diseases Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic Screening for Carrier Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Genetic Screening for Carrier Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic Screening for Carrier Diseases.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Genetic Screening for Carrier Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Genetic Screening for Carrier Diseases company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Genetic Screening for Carrier Diseases revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Genetic Screening for Carrier Diseases Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. NGS Major Player Table 3. Whole Exome Sequencing Major Player Table 4. Others Major Player Table 5. Global Genetic Screening for Carrier Diseases Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Couple Major Player Table 7. Individual Major Player Table 8. Genetic Screening for Carrier Diseases Industry Trends Table 9. Genetic Screening for Carrier Diseases Industry Drivers Table 10. Genetic Screening for Carrier Diseases Industry Opportunities and Challenges Table 11. Genetic Screening for Carrier Diseases Industry Restraints Table 12. Global Genetic Screening for Carrier Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Genetic Screening for Carrier Diseases Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Genetic Screening for Carrier Diseases Market Share by Region (2021-2026) Table 15. Global Genetic Screening for Carrier Diseases Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Genetic Screening for Carrier Diseases Market Share by Region (2027-2032) Table 17. Global Genetic Screening for Carrier Diseases Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Genetic Screening for Carrier Diseases Revenue Market Share by Players (2021-2026) Table 19. Global Genetic Screening for Carrier Diseases Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Genetic Screening for Carrier Diseases Key Players Headquarters & Area Served Table 21. Global Genetic Screening for Carrier Diseases Players, Product Type & Application Table 22. Global Genetic Screening for Carrier Diseases Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Genetic Screening for Carrier Diseases by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Genetic Screening for Carrier Diseases Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Genetic Screening for Carrier Diseases Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Genetic Screening for Carrier Diseases Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Genetic Screening for Carrier Diseases Revenue Market Share by Type (2021-2026) Table 29. Global Genetic Screening for Carrier Diseases Revenue Market Share by Type (2027-2032) Table 30. Global Genetic Screening for Carrier Diseases Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Genetic Screening for Carrier Diseases Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Genetic Screening for Carrier Diseases Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Genetic Screening for Carrier Diseases Revenue Market Share by Application (2021-2026) Table 34. Global Genetic Screening for Carrier Diseases Revenue Market Share by Application (2027-2032) Table 35. Thermo Fisher Scientific Company Information Table 36. Thermo Fisher Scientific Business Overview Table 37. Thermo Fisher Scientific Genetic Screening for Carrier Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Thermo Fisher Scientific Genetic Screening for Carrier Diseases Product Portfolio Table 39. Thermo Fisher Scientific Recent Development Table 40. Eurofins Scientific Company Information Table 41. Eurofins Scientific Business Overview Table 42. Eurofins Scientific Genetic Screening for Carrier Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Eurofins Scientific Genetic Screening for Carrier Diseases Product Portfolio Table 44. Eurofins Scientific Recent Development Table 45. Illumina Company Information Table 46. Illumina Business Overview Table 47. Illumina Genetic Screening for Carrier Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Illumina Genetic Screening for Carrier Diseases Product Portfolio Table 49. Illumina Recent Development Table 50. Invitae Company Information Table 51. Invitae Business Overview Table 52. Invitae Genetic Screening for Carrier Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Invitae Genetic Screening for Carrier Diseases Product Portfolio Table 54. Invitae Recent Development Table 55. MedGenome Company Information Table 56. MedGenome Business Overview Table 57. MedGenome Genetic Screening for Carrier Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. MedGenome Genetic Screening for Carrier Diseases Product Portfolio Table 59. MedGenome Recent Development Table 60. Myriad Genetics Company Information Table 61. Myriad Genetics Business Overview Table 62. Myriad Genetics Genetic Screening for Carrier Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Myriad Genetics Genetic Screening for Carrier Diseases Product Portfolio Table 64. Myriad Genetics Recent Development Table 65. Roche Company Information Table 66. Roche Business Overview Table 67. Roche Genetic Screening for Carrier Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Roche Genetic Screening for Carrier Diseases Product Portfolio Table 69. Roche Recent Development Table 70. Natera Company Information Table 71. Natera Business Overview Table 72. Natera Genetic Screening for Carrier Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Natera Genetic Screening for Carrier Diseases Product Portfolio Table 74. Natera Recent Development Table 75. OPKO Health Company Information Table 76. OPKO Health Business Overview Table 77. OPKO Health Genetic Screening for Carrier Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. OPKO Health Genetic Screening for Carrier Diseases Product Portfolio Table 79. OPKO Health Recent Development Table 80. 23andMe Company Information Table 81. 23andMe Business Overview Table 82. 23andMe Genetic Screening for Carrier Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. 23andMe Genetic Screening for Carrier Diseases Product Portfolio Table 84. 23andMe Recent Development Table 85. bioMérieux Company Information Table 86. bioMérieux Business Overview Table 87. bioMérieux Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. bioMérieux Genetic Screening for Carrier Diseases Product Portfolio Table 89. bioMérieux Recent Development Table 90. EKF Diagnostics Company Information Table 91. EKF Diagnostics Business Overview Table 92. EKF Diagnostics Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. EKF Diagnostics Genetic Screening for Carrier Diseases Product Portfolio Table 94. EKF Diagnostics Recent Development Table 95. Gene by Gene (myDNA) Company Information Table 96. Gene by Gene (myDNA) Business Overview Table 97. Gene by Gene (myDNA) Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Gene by Gene (myDNA) Genetic Screening for Carrier Diseases Product Portfolio Table 99. Gene by Gene (myDNA) Recent Development Table 100. Fulgent Genetics Company Information Table 101. Fulgent Genetics Business Overview Table 102. Fulgent Genetics Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Fulgent Genetics Genetic Screening for Carrier Diseases Product Portfolio Table 104. Fulgent Genetics Recent Development Table 105. NxGen MDx Company Information Table 106. NxGen MDx Business Overview Table 107. NxGen MDx Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. NxGen MDx Genetic Screening for Carrier Diseases Product Portfolio Table 109. NxGen MDx Recent Development Table 110. Sonic Genetics Company Information Table 111. Sonic Genetics Business Overview Table 112. Sonic Genetics Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Sonic Genetics Genetic Screening for Carrier Diseases Product Portfolio Table 114. Sonic Genetics Recent Development Table 115. My Baby Company Information Table 116. My Baby Business Overview Table 117. My Baby Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. My Baby Genetic Screening for Carrier Diseases Product Portfolio Table 119. My Baby Recent Development Table 120. AncestryDNA Company Information Table 121. AncestryDNA Business Overview Table 122. AncestryDNA Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. AncestryDNA Genetic Screening for Carrier Diseases Product Portfolio Table 124. AncestryDNA Recent Development Table 125. DiaSorin Company Information Table 126. DiaSorin Business Overview Table 127. DiaSorin Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. DiaSorin Genetic Screening for Carrier Diseases Product Portfolio Table 129. DiaSorin Recent Development Table 130. Grifols Company Information Table 131. Grifols Business Overview Table 132. Grifols Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Grifols Genetic Screening for Carrier Diseases Product Portfolio Table 134. Grifols Recent Development Table 135. BGI Genomics Company Information Table 136. BGI Genomics Business Overview Table 137. BGI Genomics Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. BGI Genomics Genetic Screening for Carrier Diseases Product Portfolio Table 139. BGI Genomics Recent Development Table 140. Chigene Company Information Table 141. Chigene Business Overview Table 142. Chigene Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Chigene Genetic Screening for Carrier Diseases Product Portfolio Table 144. Chigene Recent Development Table 145. Jiajian Medical Testing Company Information Table 146. Jiajian Medical Testing Business Overview Table 147. Jiajian Medical Testing Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Jiajian Medical Testing Genetic Screening for Carrier Diseases Product Portfolio Table 149. Jiajian Medical Testing Recent Development Table 150. Genesky Company Information Table 151. Genesky Business Overview Table 152. Genesky Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Genesky Genetic Screening for Carrier Diseases Product Portfolio Table 154. Genesky Recent Development Table 155. Berry Genomics Company Information Table 156. Berry Genomics Business Overview Table 157. Berry Genomics Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Berry Genomics Genetic Screening for Carrier Diseases Product Portfolio Table 159. Berry Genomics Recent Development Table 160. Weihansi Biomedical Technology Company Information Table 161. Weihansi Biomedical Technology Business Overview Table 162. Weihansi Biomedical Technology Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. Weihansi Biomedical Technology Genetic Screening for Carrier Diseases Product Portfolio Table 164. Weihansi Biomedical Technology Recent Development Table 165. Annaroad Company Information Table 166. Annaroad Business Overview Table 167. Annaroad Genetic Screening for Carrier Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. Annaroad Genetic Screening for Carrier Diseases Product Portfolio Table 169. Annaroad Recent Development Table 170. North America Genetic Screening for Carrier Diseases Revenue by Type (2021-2026) & (US$ Million) Table 171. North America Genetic Screening for Carrier Diseases Revenue by Type (2027-2032) & (US$ Million) Table 172. North America Genetic Screening for Carrier Diseases Revenue by Application (2021-2026) & (US$ Million) Table 173. North America Genetic Screening for Carrier Diseases Revenue by Application (2027-2032) & (US$ Million) Table 174. North America Genetic Screening for Carrier Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. North America Genetic Screening for Carrier Diseases Revenue by Country (2021-2026) & (US$ Million) Table 176. North America Genetic Screening for Carrier Diseases Revenue by Country (US$ Million) & (2027-2032) Table 177. Europe Genetic Screening for Carrier Diseases Revenue by Type (2021-2026) & (US$ Million) Table 178. Europe Genetic Screening for Carrier Diseases Revenue by Type (2027-2032) & (US$ Million) Table 179. Europe Genetic Screening for Carrier Diseases Revenue by Application (2021-2026) & (US$ Million) Table 180. Europe Genetic Screening for Carrier Diseases Revenue by Application (2027-2032) & (US$ Million) Table 181. Europe Genetic Screening for Carrier Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 182. Europe Genetic Screening for Carrier Diseases Revenue by Country (2021-2026) & (US$ Million) Table 183. Europe Genetic Screening for Carrier Diseases Revenue by Country (US$ Million) & (2027-2032) Table 184. China Genetic Screening for Carrier Diseases Revenue by Type (2021-2026) & (US$ Million) Table 185. China Genetic Screening for Carrier Diseases Revenue by Type (2027-2032) & (US$ Million) Table 186. China Genetic Screening for Carrier Diseases Revenue by Application (2021-2026) & (US$ Million) Table 187. China Genetic Screening for Carrier Diseases Revenue by Application (2027-2032) & (US$ Million) Table 188. Asia Genetic Screening for Carrier Diseases Revenue by Type (2021-2026) & (US$ Million) Table 189. Asia Genetic Screening for Carrier Diseases Revenue by Type (2027-2032) & (US$ Million) Table 190. Asia Genetic Screening for Carrier Diseases Revenue by Application (2021-2026) & (US$ Million) Table 191. Asia Genetic Screening for Carrier Diseases Revenue by Application (2027-2032) & (US$ Million) Table 192. Asia Genetic Screening for Carrier Diseases Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 193. Asia Genetic Screening for Carrier Diseases Revenue by Region (US$ Million) & (2021-2026) Table 194. Asia Genetic Screening for Carrier Diseases Revenue by Region (US$ Million) & (2027-2032) Table 195. SAMEA Genetic Screening for Carrier Diseases Revenue by Type (2021-2026) & (US$ Million) Table 196. SAMEA Genetic Screening for Carrier Diseases Revenue by Type (2027-2032) & (US$ Million) Table 197. SAMEA Genetic Screening for Carrier Diseases Revenue by Application (2021-2026) & (US$ Million) Table 198. SAMEA Genetic Screening for Carrier Diseases Revenue by Application (2027-2032) & (US$ Million) Table 199. SAMEA Genetic Screening for Carrier Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. SAMEA Genetic Screening for Carrier Diseases Revenue by Country (2021-2026) & (US$ Million) Table 201. SAMEA Genetic Screening for Carrier Diseases Revenue by Country (US$ Million) & (2027-2032) Table 202. Research Programs/Design for This Report Table 203. Authors List of This Report Table 204. Secondary Sources Table 205. Primary Sources List of Figures Figure 1. Genetic Screening for Carrier Diseases Image Figure 2. Global Genetic Screening for Carrier Diseases Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Genetic Screening for Carrier Diseases Market Size Share 2021 VS 2025 VS 2032 Figure 4. NGS Image Figure 5. Whole Exome Sequencing Image Figure 6. Others Image Figure 7. Global Genetic Screening for Carrier Diseases Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Genetic Screening for Carrier Diseases Market Size Share 2021 VS 2025 VS 2032 Figure 9. Couple Image Figure 10. Individual Image Figure 11. Global Genetic Screening for Carrier Diseases Market Size (US$ Million) & (2021-2032) Figure 12. Global Genetic Screening for Carrier Diseases Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Genetic Screening for Carrier Diseases Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Genetic Screening for Carrier Diseases Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Genetic Screening for Carrier Diseases Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Genetic Screening for Carrier Diseases Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Genetic Screening for Carrier Diseases Revenue Market Share by Type (2021-2032) Figure 19. Global Genetic Screening for Carrier Diseases Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Genetic Screening for Carrier Diseases Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Genetic Screening for Carrier Diseases Revenue Market Share by Application (2021-2032) Figure 22. North America Genetic Screening for Carrier Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Genetic Screening for Carrier Diseases Revenue Share by Type (2021-2032) Figure 24. North America Genetic Screening for Carrier Diseases Revenue Share by Application (2021-2032) Figure 25. North America Genetic Screening for Carrier Diseases Revenue Share by Country (2021-2032) Figure 26. United States Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Genetic Screening for Carrier Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Genetic Screening for Carrier Diseases Revenue Share by Type (2021-2032) Figure 31. Europe Genetic Screening for Carrier Diseases Revenue Share by Application (2021-2032) Figure 32. Europe Genetic Screening for Carrier Diseases Revenue Share by Country (2021-2032) Figure 33. Germany Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Genetic Screening for Carrier Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Genetic Screening for Carrier Diseases Revenue Share by Type (2021-2032) Figure 43. China Genetic Screening for Carrier Diseases Revenue Share by Application (2021-2032) Figure 44. Asia Genetic Screening for Carrier Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Genetic Screening for Carrier Diseases Revenue Share by Type (2021-2032) Figure 46. Asia Genetic Screening for Carrier Diseases Revenue Share by Application (2021-2032) Figure 47. Asia Genetic Screening for Carrier Diseases Revenue Share by Region (2021-2032) Figure 48. Japan Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Genetic Screening for Carrier Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Genetic Screening for Carrier Diseases Revenue Share by Type (2021-2032) Figure 56. SAMEA Genetic Screening for Carrier Diseases Revenue Share by Application (2021-2032) Figure 57. SAMEA Genetic Screening for Carrier Diseases Revenue Share by Country (2021-2032) Figure 58. Brazil Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Genetic Screening for Carrier Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • NGS
  • Whole Exome Sequencing
  • Others
Applications
  • Couple
  • Individual
Companies covered
  • Thermo Fisher Scientific
  • Eurofins Scientific
  • Illumina
  • Invitae
  • MedGenome
  • Myriad Genetics
  • Roche
  • Natera
  • OPKO Health
  • 23andMe
  • bioMérieux
  • EKF Diagnostics
  • Gene by Gene (myDNA)
  • Fulgent Genetics
  • NxGen MDx
  • Sonic Genetics
  • My Baby
  • AncestryDNA
  • DiaSorin
  • Grifols
  • BGI Genomics
  • Chigene
  • Jiajian Medical Testing
  • Genesky
  • Berry Genomics
  • Weihansi Biomedical Technology
  • Annaroad

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Genetic Screening for Carrier Diseases Market by Type
  3. 1.2.1 Global Genetic Screening for Carrier Diseases Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 NGS
  5. 1.2.3 Whole Exome Sequencing
  6. 1.2.4 Others
  7. 1.3 Genetic Screening for Carrier Diseases Market by Application
  8. 1.3.1 Global Genetic Screening for Carrier Diseases Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Couple
  10. 1.3.3 Individual
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Genetic Screening for Carrier Diseases Market Dynamics
  1. 2.1 Genetic Screening for Carrier Diseases Industry Trends
  2. 2.2 Genetic Screening for Carrier Diseases Industry Drivers
  3. 2.3 Genetic Screening for Carrier Diseases Industry Opportunities and Challenges
  4. 2.4 Genetic Screening for Carrier Diseases Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Genetic Screening for Carrier Diseases Market Perspective (2021-2032)
  2. 3.2 Global Genetic Screening for Carrier Diseases Growth Trends by Region
  3. 3.2.1 Global Genetic Screening for Carrier Diseases Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Genetic Screening for Carrier Diseases Market Size by Region (2021-2026)
  5. 3.2.3 Global Genetic Screening for Carrier Diseases Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Genetic Screening for Carrier Diseases Revenue by Players
  2. 4.1.1 Global Genetic Screening for Carrier Diseases Revenue by Players (2021-2026)
  3. 4.1.2 Global Genetic Screening for Carrier Diseases Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Genetic Screening for Carrier Diseases Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Genetic Screening for Carrier Diseases Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Genetic Screening for Carrier Diseases Key Players Headquarters & Area Served
  7. 4.4 Global Genetic Screening for Carrier Diseases Players, Product Type & Application
  8. 4.5 Global Genetic Screening for Carrier Diseases Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Genetic Screening for Carrier Diseases Market CR5 and HHI
  11. 4.6.3 2025 Genetic Screening for Carrier Diseases Tier 1, Tier 2, and Tier 3
5 Genetic Screening for Carrier Diseases Market Size by Type
  1. 5.1 Global Genetic Screening for Carrier Diseases Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Genetic Screening for Carrier Diseases Revenue by Type (2021-2032)
  3. 5.3 Global Genetic Screening for Carrier Diseases Revenue Market Share by Type (2021-2032)
6 Genetic Screening for Carrier Diseases Market Size by Application
  1. 6.1 Global Genetic Screening for Carrier Diseases Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Genetic Screening for Carrier Diseases Revenue by Application (2021-2032)
  3. 6.3 Global Genetic Screening for Carrier Diseases Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Thermo Fisher Scientific
  2. 7.1.1 Thermo Fisher Scientific Company Information
  3. 7.1.2 Thermo Fisher Scientific Business Overview
  4. 7.1.3 Thermo Fisher Scientific Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Thermo Fisher Scientific Genetic Screening for Carrier Diseases Product Portfolio
  6. 7.1.5 Thermo Fisher Scientific Recent Developments
  7. 7.2 Eurofins Scientific
  8. 7.2.1 Eurofins Scientific Company Information
  9. 7.2.2 Eurofins Scientific Business Overview
  10. 7.2.3 Eurofins Scientific Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eurofins Scientific Genetic Screening for Carrier Diseases Product Portfolio
  12. 7.2.5 Eurofins Scientific Recent Developments
  13. 7.3 Illumina
  14. 7.3.1 Illumina Company Information
  15. 7.3.2 Illumina Business Overview
  16. 7.3.3 Illumina Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Illumina Genetic Screening for Carrier Diseases Product Portfolio
  18. 7.3.5 Illumina Recent Developments
  19. 7.4 Invitae
  20. 7.4.1 Invitae Company Information
  21. 7.4.2 Invitae Business Overview
  22. 7.4.3 Invitae Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Invitae Genetic Screening for Carrier Diseases Product Portfolio
  24. 7.4.5 Invitae Recent Developments
  25. 7.5 MedGenome
  26. 7.5.1 MedGenome Company Information
  27. 7.5.2 MedGenome Business Overview
  28. 7.5.3 MedGenome Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  29. 7.5.4 MedGenome Genetic Screening for Carrier Diseases Product Portfolio
  30. 7.5.5 MedGenome Recent Developments
  31. 7.6 Myriad Genetics
  32. 7.6.1 Myriad Genetics Company Information
  33. 7.6.2 Myriad Genetics Business Overview
  34. 7.6.3 Myriad Genetics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Myriad Genetics Genetic Screening for Carrier Diseases Product Portfolio
  36. 7.6.5 Myriad Genetics Recent Developments
  37. 7.7 Roche
  38. 7.7.1 Roche Company Information
  39. 7.7.2 Roche Business Overview
  40. 7.7.3 Roche Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Roche Genetic Screening for Carrier Diseases Product Portfolio
  42. 7.7.5 Roche Recent Developments
  43. 7.8 Natera
  44. 7.8.1 Natera Company Information
  45. 7.8.2 Natera Business Overview
  46. 7.8.3 Natera Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Natera Genetic Screening for Carrier Diseases Product Portfolio
  48. 7.8.5 Natera Recent Developments
  49. 7.9 OPKO Health
  50. 7.9.1 OPKO Health Company Information
  51. 7.9.2 OPKO Health Business Overview
  52. 7.9.3 OPKO Health Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  53. 7.9.4 OPKO Health Genetic Screening for Carrier Diseases Product Portfolio
  54. 7.9.5 OPKO Health Recent Developments
  55. 7.10 23andMe
  56. 7.10.1 23andMe Company Information
  57. 7.10.2 23andMe Business Overview
  58. 7.10.3 23andMe Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  59. 7.10.4 23andMe Genetic Screening for Carrier Diseases Product Portfolio
  60. 7.10.5 23andMe Recent Developments
  61. 7.11 bioMérieux
  62. 7.11.1 bioMérieux Company Information
  63. 7.11.2 bioMérieux Business Overview
  64. 7.11.3 bioMérieux Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  65. 7.11.4 bioMérieux Genetic Screening for Carrier Diseases Product Portfolio
  66. 7.11.5 bioMérieux Recent Developments
  67. 7.12 EKF Diagnostics
  68. 7.12.1 EKF Diagnostics Company Information
  69. 7.12.2 EKF Diagnostics Business Overview
  70. 7.12.3 EKF Diagnostics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  71. 7.12.4 EKF Diagnostics Genetic Screening for Carrier Diseases Product Portfolio
  72. 7.12.5 EKF Diagnostics Recent Developments
  73. 7.13 Gene by Gene (myDNA)
  74. 7.13.1 Gene by Gene (myDNA) Company Information
  75. 7.13.2 Gene by Gene (myDNA) Business Overview
  76. 7.13.3 Gene by Gene (myDNA) Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Gene by Gene (myDNA) Genetic Screening for Carrier Diseases Product Portfolio
  78. 7.13.5 Gene by Gene (myDNA) Recent Developments
  79. 7.14 Fulgent Genetics
  80. 7.14.1 Fulgent Genetics Company Information
  81. 7.14.2 Fulgent Genetics Business Overview
  82. 7.14.3 Fulgent Genetics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Fulgent Genetics Genetic Screening for Carrier Diseases Product Portfolio
  84. 7.14.5 Fulgent Genetics Recent Developments
  85. 7.15 NxGen MDx
  86. 7.15.1 NxGen MDx Company Information
  87. 7.15.2 NxGen MDx Business Overview
  88. 7.15.3 NxGen MDx Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  89. 7.15.4 NxGen MDx Genetic Screening for Carrier Diseases Product Portfolio
  90. 7.15.5 NxGen MDx Recent Developments
  91. 7.16 Sonic Genetics
  92. 7.16.1 Sonic Genetics Company Information
  93. 7.16.2 Sonic Genetics Business Overview
  94. 7.16.3 Sonic Genetics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Sonic Genetics Genetic Screening for Carrier Diseases Product Portfolio
  96. 7.16.5 Sonic Genetics Recent Developments
  97. 7.17 My Baby
  98. 7.17.1 My Baby Company Information
  99. 7.17.2 My Baby Business Overview
  100. 7.17.3 My Baby Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  101. 7.17.4 My Baby Genetic Screening for Carrier Diseases Product Portfolio
  102. 7.17.5 My Baby Recent Developments
  103. 7.18 AncestryDNA
  104. 7.18.1 AncestryDNA Company Information
  105. 7.18.2 AncestryDNA Business Overview
  106. 7.18.3 AncestryDNA Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  107. 7.18.4 AncestryDNA Genetic Screening for Carrier Diseases Product Portfolio
  108. 7.18.5 AncestryDNA Recent Developments
  109. 7.19 DiaSorin
  110. 7.19.1 DiaSorin Company Information
  111. 7.19.2 DiaSorin Business Overview
  112. 7.19.3 DiaSorin Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  113. 7.19.4 DiaSorin Genetic Screening for Carrier Diseases Product Portfolio
  114. 7.19.5 DiaSorin Recent Developments
  115. 7.20 Grifols
  116. 7.20.1 Grifols Company Information
  117. 7.20.2 Grifols Business Overview
  118. 7.20.3 Grifols Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Grifols Genetic Screening for Carrier Diseases Product Portfolio
  120. 7.20.5 Grifols Recent Developments
  121. 7.21 BGI Genomics
  122. 7.21.1 BGI Genomics Company Information
  123. 7.21.2 BGI Genomics Business Overview
  124. 7.21.3 BGI Genomics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  125. 7.21.4 BGI Genomics Genetic Screening for Carrier Diseases Product Portfolio
  126. 7.21.5 BGI Genomics Recent Developments
  127. 7.22 Chigene
  128. 7.22.1 Chigene Company Information
  129. 7.22.2 Chigene Business Overview
  130. 7.22.3 Chigene Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Chigene Genetic Screening for Carrier Diseases Product Portfolio
  132. 7.22.5 Chigene Recent Developments
  133. 7.23 Jiajian Medical Testing
  134. 7.23.1 Jiajian Medical Testing Company Information
  135. 7.23.2 Jiajian Medical Testing Business Overview
  136. 7.23.3 Jiajian Medical Testing Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Jiajian Medical Testing Genetic Screening for Carrier Diseases Product Portfolio
  138. 7.23.5 Jiajian Medical Testing Recent Developments
  139. 7.24 Genesky
  140. 7.24.1 Genesky Company Information
  141. 7.24.2 Genesky Business Overview
  142. 7.24.3 Genesky Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  143. 7.24.4 Genesky Genetic Screening for Carrier Diseases Product Portfolio
  144. 7.24.5 Genesky Recent Developments
  145. 7.25 Berry Genomics
  146. 7.25.1 Berry Genomics Company Information
  147. 7.25.2 Berry Genomics Business Overview
  148. 7.25.3 Berry Genomics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  149. 7.25.4 Berry Genomics Genetic Screening for Carrier Diseases Product Portfolio
  150. 7.25.5 Berry Genomics Recent Developments
  151. 7.26 Weihansi Biomedical Technology
  152. 7.26.1 Weihansi Biomedical Technology Company Information
  153. 7.26.2 Weihansi Biomedical Technology Business Overview
  154. 7.26.3 Weihansi Biomedical Technology Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  155. 7.26.4 Weihansi Biomedical Technology Genetic Screening for Carrier Diseases Product Portfolio
  156. 7.26.5 Weihansi Biomedical Technology Recent Developments
  157. 7.27 Annaroad
  158. 7.27.1 Annaroad Company Information
  159. 7.27.2 Annaroad Business Overview
  160. 7.27.3 Annaroad Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  161. 7.27.4 Annaroad Genetic Screening for Carrier Diseases Product Portfolio
  162. 7.27.5 Annaroad Recent Developments
8 North America
  1. 8.1 North America Genetic Screening for Carrier Diseases Revenue (2021-2032)
  2. 8.2 North America Genetic Screening for Carrier Diseases Revenue by Type (2021-2032)
  3. 8.2.1 North America Genetic Screening for Carrier Diseases Revenue by Type (2021-2026)
  4. 8.2.2 North America Genetic Screening for Carrier Diseases Revenue by Type (2027-2032)
  5. 8.3 North America Genetic Screening for Carrier Diseases Revenue Share by Type (2021-2032)
  6. 8.4 North America Genetic Screening for Carrier Diseases Revenue by Application (2021-2032)
  7. 8.4.1 North America Genetic Screening for Carrier Diseases Revenue by Application (2021-2026)
  8. 8.4.2 North America Genetic Screening for Carrier Diseases Revenue by Application (2027-2032)
  9. 8.5 North America Genetic Screening for Carrier Diseases Revenue Share by Application (2021-2032)
  10. 8.6 North America Genetic Screening for Carrier Diseases Revenue by Country
  11. 8.6.1 North America Genetic Screening for Carrier Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Genetic Screening for Carrier Diseases Revenue by Country (2021-2026)
  13. 8.6.3 North America Genetic Screening for Carrier Diseases Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Genetic Screening for Carrier Diseases Revenue (2021-2032)
  2. 9.2 Europe Genetic Screening for Carrier Diseases Revenue by Type (2021-2032)
  3. 9.2.1 Europe Genetic Screening for Carrier Diseases Revenue by Type (2021-2026)
  4. 9.2.2 Europe Genetic Screening for Carrier Diseases Revenue by Type (2027-2032)
  5. 9.3 Europe Genetic Screening for Carrier Diseases Revenue Share by Type (2021-2032)
  6. 9.4 Europe Genetic Screening for Carrier Diseases Revenue by Application (2021-2032)
  7. 9.4.1 Europe Genetic Screening for Carrier Diseases Revenue by Application (2021-2026)
  8. 9.4.2 Europe Genetic Screening for Carrier Diseases Revenue by Application (2027-2032)
  9. 9.5 Europe Genetic Screening for Carrier Diseases Revenue Share by Application (2021-2032)
  10. 9.6 Europe Genetic Screening for Carrier Diseases Revenue by Country
  11. 9.6.1 Europe Genetic Screening for Carrier Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Genetic Screening for Carrier Diseases Revenue by Country (2021-2026)
  13. 9.6.3 Europe Genetic Screening for Carrier Diseases Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Genetic Screening for Carrier Diseases Revenue (2021-2032)
  2. 10.2 China Genetic Screening for Carrier Diseases Revenue by Type (2021-2032)
  3. 10.2.1 China Genetic Screening for Carrier Diseases Revenue by Type (2021-2026)
  4. 10.2.2 China Genetic Screening for Carrier Diseases Revenue by Type (2027-2032)
  5. 10.3 China Genetic Screening for Carrier Diseases Revenue Share by Type (2021-2032)
  6. 10.4 China Genetic Screening for Carrier Diseases Revenue by Application (2021-2032)
  7. 10.4.1 China Genetic Screening for Carrier Diseases Revenue by Application (2021-2026)
  8. 10.4.2 China Genetic Screening for Carrier Diseases Revenue by Application (2027-2032)
  9. 10.5 China Genetic Screening for Carrier Diseases Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Genetic Screening for Carrier Diseases Revenue (2021-2032)
  2. 11.2 Asia Genetic Screening for Carrier Diseases Revenue by Type (2021-2032)
  3. 11.2.1 Asia Genetic Screening for Carrier Diseases Revenue by Type (2021-2026)
  4. 11.2.2 Asia Genetic Screening for Carrier Diseases Revenue by Type (2027-2032)
  5. 11.3 Asia Genetic Screening for Carrier Diseases Revenue Share by Type (2021-2032)
  6. 11.4 Asia Genetic Screening for Carrier Diseases Revenue by Application (2021-2032)
  7. 11.4.1 Asia Genetic Screening for Carrier Diseases Revenue by Application (2021-2026)
  8. 11.4.2 Asia Genetic Screening for Carrier Diseases Revenue by Application (2027-2032)
  9. 11.5 Asia Genetic Screening for Carrier Diseases Revenue Share by Application (2021-2032)
  10. 11.6 Asia Genetic Screening for Carrier Diseases Revenue by Country
  11. 11.6.1 Asia Genetic Screening for Carrier Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Genetic Screening for Carrier Diseases Revenue by Country (2021-2026)
  13. 11.6.3 Asia Genetic Screening for Carrier Diseases Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Genetic Screening for Carrier Diseases Revenue (2021-2032)
  2. 12.2 SAMEA Genetic Screening for Carrier Diseases Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Genetic Screening for Carrier Diseases Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Genetic Screening for Carrier Diseases Revenue by Type (2027-2032)
  5. 12.3 SAMEA Genetic Screening for Carrier Diseases Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Genetic Screening for Carrier Diseases Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Genetic Screening for Carrier Diseases Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Genetic Screening for Carrier Diseases Revenue by Application (2027-2032)
  9. 12.5 SAMEA Genetic Screening for Carrier Diseases Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Genetic Screening for Carrier Diseases Revenue by Country
  11. 12.6.1 SAMEA Genetic Screening for Carrier Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Genetic Screening for Carrier Diseases Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Genetic Screening for Carrier Diseases Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst